
BIOA Stock Forecast & Price Target
BIOA Analyst Ratings
Bulls say
Bioage Labs is well positioned for success due to their innovative approach to targeting the biology of human aging, evidenced by their promising drug, BGE-102, and their focus on developing therapeutic products for metabolic diseases. The company's strategic partnerships and continued development of other potential treatments for obesity and ophthalmology demonstrate their commitment to sustained growth and expansion in the biopharmaceutical industry. With solid financials and promising clinical results, Bioage Labs is an attractive investment for those looking to capitalize on the rapidly growing field of anti-aging therapeutics.
Bears say
Bioage Labs is a biopharmaceutical company with a promising pipeline of treatments for metabolic diseases based on longitudinal human data. While their recent financial statement and enrollment progress are positive indicators, the risk of liver toxicity in early drug development and previous setbacks with VTX3232 are concerning. However, with multiple partnerships and a potential for identifying new targets, Bioage Labs has the potential for long-term success in the future.
This aggregate rating is based on analysts' research of BioAge Labs Inc and is not a guaranteed prediction by Public.com or investment advice.
BIOA Analyst Forecast & Price Prediction
Start investing in BIOA
Order type
Buy in
Order amount
Est. shares
0 shares